/

Empresas

NM

Empresas

NMS GROUP S.P.A.

Sobre qué escribimos

ArteCulturaOncologíaSaludSanidad

33 Comunicados de prensa

Ver todos los comunicados de prensa

Press Release cover image

31/03/2025

Salud

Oncología

Sanidad

Nerviano Medical Sciences Srl Announces Rozlytrek® (Entrectinib) Royalty Agreement - NMS Group

Fuente

NMS GROUP S.P.A.

1,00

0

Press Release cover image

21/02/2025

Arte

Cultura

Arqueología

Legislación/Derecho

CPhI Japan 2025 - NMS Group

Fuente

NMS GROUP S.P.A.

1,00

0

Press Release cover image

19/02/2025

Arte

Cultura

Legislación/Derecho

Espacio aéreo

DCAT WEEK 2025 - NMS Group

Fuente

NMS GROUP S.P.A.

1,00

0

Press Release cover image

10/02/2025

Salud

Oncología

Sanidad

PARP1 publications - NMS Group

Fuente

NMS GROUP S.P.A.

1,00

0

Press Release cover image

31/01/2025

Salud

Oncología

Sanidad

Nerviano Medical Sciences’ presentation from the 8th Annual DDR Inhibitors Summit is now available - NMS Group

Fuente

NMS GROUP S.P.A.

1,00

0

Press Release cover image

22/01/2025

Salud

Oncología

Sanidad

Nerviano Medical Sciences is presenting at the 8th Annual DDR Inhibitors Summit - NMS Group

Fuente

NMS GROUP S.P.A.

1,00

0

Press Release cover image

13/01/2025

Salud

Oncología

Sanidad

Nerviano Medical Sciences announces FDA clearance of two INDs for its PARP1-selective, non-trapping inhibitor NMS-293 to start clinical studies in small cell lung cancer and BRCA wild-type ovarian carcinoma - NMS Group

Fuente

NMS GROUP S.P.A.

1,00

0

Press Release cover image

07/01/2025

Salud

Oncología

Sanidad

Nerviano Medical Sciences S.r.l. Announces the Launch of a New Clinical Trial to Evaluate NMS-153 in Combination with Atezolizumab and Clinical Trial Supply Agreement with Roche - NMS Group

Fuente

NMS GROUP S.P.A.

1,00

0

Press Release cover image

25/11/2024

Salud

Sanidad

Nerviano Medical Sciences (NMS) to Reacquire World-Wide Rights of NMS-293, a Potent, Highly Selective, Non-Trapping, Brain-Penetrant PARP1 Inhibitor with Promising Clinical Results - NMS Group

Fuente

NMS GROUP S.P.A.

1,00

0

Press Release cover image

25/11/2024

Salud

Sanidad

Nerviano Medical Sciences (NMS) to Reacquire World-Wide Rights of NMS-293, a Potent, Highly Selective, Non-Trapping, Brain-Penetrant PARP1 Inhibitor with Promising Clinical Results - NMS Group

Fuente

NMS GROUP S.P.A.

1,00

0

Seguidores

0

Compatibilidad

0